Core Viewpoint - The National Organization for Drug Procurement Office has launched the 11th batch of national centralized drug procurement, focusing on ensuring clinical demand and quality while preventing price wars and promoting fair competition [1][2] Group 1: Procurement Details - The 11th batch aims to procure 55 drug varieties, with over 46,000 medical institutions participating in the bidding process, where more than 70% of the bids are based on specific brand names [1] - Medical institutions can now choose to bid either by drug generic names or specific brand names, enhancing the alignment between clinical needs and supply [1][2] Group 2: Quality Assurance Measures - New quality assurance measures include stricter requirements for production experience, higher GMP standards for production lines, and comprehensive sampling inspections for selected products and companies [2] - Changes also include transparency in the production process, requiring public disclosure of any changes in raw materials, auxiliary materials, packaging, and processes [2] Group 3: Pricing and Competition - The procurement rules have shifted away from a "lowest bid" approach to a model that uses "50% of the average successful bid" as a pricing anchor, aiming to prevent abnormal low pricing from disrupting fair competition [2] - The procurement process will enhance the execution of selected results, with channels established for medical institutions and selected companies to report issues related to the execution of procurement results [2]
第十一批国家组织药品集中采购工作开展 明确破除“中标唯低价论”
Yang Guang Wang·2025-09-21 01:03